Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) Advancements & Future Forecasts through 2030

DUBLIN, March 29, 2024 /PRNewswire/ — The “Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) – Advances & Applications, 2023” report has been added to ResearchAndMarkets.com’s offering.

MSCs appear to be an exceptionally promising tool for cell therapy, because of their unusual advantages, which include availability, expandability, transplantability, and ethical implications. Interest in therapeutic applications of human MSCs arises from their diverse ability to impact human health, as well as their ability to migrate to sites of tissue injury/inflammation or tumor growth. MSCs are essential raw materials for many regenerative medicine products, including cell-based therapies, engineered tissues, exosome products, cosmeceuticals, and cultured meat production. MSCs are also well-suited for use in the exponential growth field of 3D printing and numerous companies are working on manufacturing technologies to support the commercial-scale production of MSCs.

Today, numerous market competitors are also exploring commercialization strategies for MSC-derived extracellular vesicles (EVs) and exosomes, because these extracellular “packages” represent a novel strategy for accessing the therapeutic effects of MSCs without the risks of administering whole cells to patients. Gene editing of MSCs for overexpressing antitumor genes or therapeutic factors is broadening their application as well. Despite the challenges associated with commercializing MSC-based therapeutics, there are more than 100,000 scientific publications published about MSCs and over 1,100 MSC-based clinical trials underway worldwide. Clinical trials involving MSC therapeutics have risen in recent years, in part due to trials related to COVID-19. Current “hotspots” for MSC clinical trials include the U.S., E.U., China, Middle East, and South Korea. While many early-stage MSC trials have demonstrated safety and efficacy, only a small number of MSC products have reached commercialization, indicating that the therapeutic market for MSCs remains early-stage. The first MSC-based cell therapy product was approved in 2010 in South Korea. To date, ten MSC-based cell therapy products have gained approval, as well as 19 MSC-based bone matrices.

While therapeutic success has been challenging, the demand for MSC-based research products has surged in recent years, with most large research product suppliers now offering a variety of MSC-based products, services, kits, and manufacturing tools. Major players involved in the market for MSC-based research products include Lonza, Thermo Fisher Scientific, Sigma Aldrich, VWR, Sartorius, ATCC, EMD Millipore, and others. Smaller and mid-sized players are also competing in this promising market, including but not limited to Axol Bioscience, StemBioSys, PromoCell, and iXCell Biotechnologies. To date, the company to establish itself with the greatest domain knowledge in the area of MSC-based products and manufacturing technologies is RoosterBio, headquartered in Frederick, Maryland, USA.

Cynata Therapeutics is also working diligently on technologies to enable large-scale production of MSC-based therapeutics, although it is exclusively focused on MSC-based therapeutics and is using its CymerusT platform technology to produce nearly infinite numbers of iPSC-derived MSCs. It is concurrently pursuing several clinical trials worldwide. In the coming years, an increasing number of research products and therapeutic products will continue to be developed around MSCs and their differentiated cell types.

Within this rapidly changing landscape, having a thorough understanding of the competition is essential. Therefore, this global strategic report details the activities of 113 leading MSC companies, including their core technologies and products under development. It presents detailed market size figures for the global MSC market, segmented by Geography and Business Segment, and accompanied by future forecasts through 2030.

This global strategic report includes:

Market size determination for the global MSC market, segmented by Geography and Business Segment
Future forecasts for the Global MSC Market through 2030
Major diseases addressed by MSCs in the ongoing clinical trials
Cost of manufacturing autologous and allogeneic MSCs
Rates, quantities, geographic locations, and types of MSC clinical trials
Types and sources of MSC industry funding
Detailed MSC patent analysis, including rates and geographic breakdown of MSC patents
The top owners, inventors, and sponsors of MSC patents
Recent business developments related to MSCs, including strategic collaborations and partnerships
MSC-based products with marketing approval and the companies commercializing them
Currently marketed MSC-based bone matrices
Pricing comparison of MSC-based products with marketing approval
The pipeline for MSC-based therapeutics
Emerging applications for MSCs, including genetic modification, 3D bioprinting, clean meat production, and cosmeceuticals
Company profiles for MSC market competitors, including their products, services, and technologies under development
Dozens of charts, figures, and tables
And so much more

In summary, this global strategic report presents market size figures with forecasts through 2030, as well as rates of MSC clinical trials, scientific publications, patents, funding events, and strategic collaborations. It also presents the pipeline for MSC-based therapeutics, identifies leading market competitors, and explores future directions for the industry at large. With the competitive nature of this global market, you don’t have the time to do the research. Claim this report to become immediately informed, without sacrificing hours of unnecessary research or missing critical opportunities.

Key Topics Covered:

1. REPORT OVERVIEW

2. MESENCHYMAL STEM CELLS (MSCS): AN OVERVIEW

3. PUBLISHED SCIENTIFIC PAPERS ON MSCS

4. STEM CELLS PATENT LANDSCAPE: AN OVERVIEW

4.1 Geographical Distribution of Stem Cell Patent Filing

4.2 MSC Patents

5. MSCS: CLINICAL TRIAL LANDSCAPE

5.1 Analysis of Data from ClinicalTrials.gov

5.2 Administration of MSCs in Clinical Trials

5.3 MSC Clinical Trials by Disease Category

6. BIOENGINEERING SOLUTIONS TO BOOST MSC’S FUNCTIONS

6.1 Small-Molecule Priming

6.2 Particle Engineering

6.3 Genetic Engineering

6.4 Bioengineering Approaches to Improve MSC Administration

7. MANUFACTURING OF MSCS

7.1 Autologous and Allogeneic MSCs

7.2 Methods of Isolation of MSCs

7.3 Cell Expansion: Conventional Cultures to Bioreactors

7.4 Bioreactors in Current Use

7.5 Main Features of Commercial Bioreactors

7.6 Number of Cells per Batch by Technologies

7.7 Microcarriers for the Expansion of MSCs

7.8 Downstream Processing of MSCs

7.9 Autologous & Allogeneic MSC Manufacturing: A Comparison

7.10 Cost Breakdown in MSC Manufacturing

8. SMALL SCALE PROCESSING OF MSCS

8.1 Model Design

8.2 Culture Media

9. LARGE-SCALE MANUFACTURING OF MSCS

9.1 The Four Common Bioprocessing Strategies for Large-Scale Expansion of MSCs

9.2 Commonly Used Sources of MSCs for Large-Scale Expansion

9.3 Commonly used Culture Media for Large-Scale Expansion of MSCs

9.3.1 Expansion Ratios Achieved with Different Culture Media

9.4 Comparison between the Four Large-Scale MSC Expansion Strategies

10. CONTRACT MANUFACTURING FOR CELL & GENE THERAPIES

10.1 The Need for Staff with Expertise

10.2 Capacity Constraints

10.3 CDMO Platforms Showing Greatest Growth Potential

10.4 Outsourcing Trends for Cell & Gene Therapies (CGT)

10.5 CMOs/CDMOs

10.6 Global Bioprocessing Capacity

10.7 Top Global CDMOs in 2022

10.8 U.K.’s Domination in European Cell & Gene Therapy Contract Manufacturing

11. MAJOR DISEASES ADDRESSED BY MSCS

12. CURRENT STATUS OF MESENCHYMAL STEM CELL INDUSTRY

12.1 Brief Account of Modified MSCs

12.2 MSC-Based Products with Marketing Approval

12.3 Currently Marketed MSC-Based Bone Matrices

13. RECENT COLLABORATIONS IN MSC SECTOR

14. MARKET ANALYSIS

14.1 Price Tags of MSC-Based CT Treatment

14.2 Price Tags of MSC-Based Matrices

14.3 Market Size of MSC-Based Therapies

14.4 Global Market for MSC-Based Therapeutics

14.5 Global Demand for Mesenchymal Stem Cells (MSCs)

15. COMPANY PROFILES

101 Bio
AGC Biologics
AMS Biotechnology
AQ Skin Solutions
AbbVie
Abzena
Adipomics
Advancells
Advent Bio
Aegle Therapeutics
Aethlon Medical
AgeX Therapeutics
AlloSource
Ambulero
American CryoStem Corporation
American Type Culture Collection (ATCC)
Andelyn Biosciences
Anemocyte
Anterogen
Arranta Bio
Aruna Bio
Avid Bioservices
Bacthera
Baylx, Inc.
Bio-Techne
BioCardia
BioCentriq
BioEden, Inc.
BioRestorative Therapies
Bioinova
Bioscience Institute
Blue Horizon International
Boehringer Ingelheim BioXcellence
Bonus Biogroup, Ltd.
BrainStorm Cell Therapeutics
CCRM
CardioCell, LLC
Caregen Nordic
Catalent Pharma Solutions
CellResearch
Cellipont Bioservices
Celltex Therapeutics
Cellular Biomedicine Group
Celprogen, Inc.
Charles River Laboratories International, Inc.
Citius Pharmaceuticals, Inc.
Corestem, Inc.
Creative Bioarray
Cynata Therapeutics, Ltd.
Cytovance Biologics
Dendreon
Direct Biologics
EXOSOMEplus
ElevateBio
Exothera
FUJIFILM Cellular Dynamics
Fujifilm Diosynth Biotechnologies
Future Cell Japan Co., Ltd.
Genezen
Hope Biosciences
Invitrx Therapeutics
JCR Pharmaceuticals
Just-Evotec Biologics
Kimera Labs
LifeCell
Longeveron
Lonza Group, Ltd.
Lorem Cytori USA, Inc.
Lykan Bioscience
Matica Biotechnology, Inc.
Medipost, Co., Ltd.
Mesoblast, Ltd.
MilliporeSigma
NecstGen
Novus Biologicals
NuVasive
Orthofix Medical
Personal Cell Sciences
Personalized Stem Cells
Pluristem Therapeutics
Porton Advanced
PromoCell
Regeneus
Reliance Life Sciences
Rentschler Biopharma
Resilience
Richter-HELM
RoosterBio, Inc.
RoslinCT
STEMCELL Technologies, Inc.
Samsung Biologics
Sentien Biotechnologies, Inc.
Smith & Nephew plc
Stemedica Cell Technologies, Inc.
Stemmatters
Stempeutics Research Pvt. Ltd.
Symbiosis Pharmaceutical
Syngene International Ltd.
TaiwanBio Therapeutics
Takeda Pharmaceutical
Tempo Bioscience
Thermo Fisher Scientific
TranstoxBio
VIVEbiotech
Viralgen
Waisman Biomanufacturing
WuXi Biologics
Yapan Bio
Yposkesi
Zimmer Biomet Holdings

For more information about this report visit https://www.researchandmarkets.com/r/2t5htn

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets

Laura Wood, Senior Manager

[email protected]

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/mesenchymal-stem-cells–medicinal-signaling-cells-mscs-advancements–future-forecasts-through-2030-302102458.html